Member Info for TWatcher

"where is wallbrook"

Good to see mologic get their CE approval, even though they are a couple of months late (A presentation by them in OCT suggested it would happen at the end of that month). Wallbrook represent ODX, not mologic. ODx have said that after they do the TT, which includes doing 3 batches and having mologic confirm that they match the mologic standard, then ODX have to independently apply for CE approval for their version.

There is no christmas present, and CK clearly failed to mention christmas in the last presentation, indicating that JAN was the timeframe for TT completion. Why people have kept wittering on about this, I don't know.

There is no information regarding whether ODX will be able to piggyback on any trials that Mologic has done for their test, or whether ODX will have to independently get into trials for their own variant.

And we STILL dont know if the mologic test is one of the 3 or 4 that are at stage 3 in the gov system. The only known one at stage 4 is the innova one, which has garnered many £100M sales at this point from UK gov.

Given the innova one has been thus far considered good enough to get these orders, we can but hope that it costs an arm and a leg, and thus the uk gov wants a cheaper solution, as there is no other reason to switch from a good enough test.

And we don't know if ODX will be in competition with Mologic for UK tenders.

So a LOT of steps to happen before the odx test *might* get a uk tender.

And unless it happens within the next couple of hrs, no announcement from ABI that they have MHRA approval for the antibody test by the contract stipulation of the 25th dec. That means UK gov can trigger cancellation of antibody orders from the consortium if it suits them to do so.

So its definitely a different christmas in many ways.

‘For some reason I have a feeling’

Thanks for that informative post (he specifically asked to be thanked later).

Next up, the chat group analysises Jholder dreams.

I guess the obvious question is, if you've drunk coke sometime (how long ?...how much?) before the test, does it make the test pointless. ?

Can I sum up your post in one sentence. You asked if they plan to work 7 or 5 days a week (even though ALL job vacancies specially say no weekend work), and the PR company told you they can’t tell you.

‘Actual orders’
It’s christmas that’s coming, not April fools !

At the time of signing the contract, DHSC clearly thought that MHRA approval by that time was important, as they included that condition into the contract. So it is certainly relevant. The question is simply one of whether the DHSC sees that condition as still relevant next week when the date is hit.

Also don’t the markets close all day on the 24th ? Or is it only 1/2 day.

A general benefit for us from Abingdon entering AIM, is that any price sensitive news regarding RTC will release under RNS rules, ie pretty much as soon as it occurs, whereas prior to this ODX news relating to RTC was hindered until Abingdon decided to release it

‘For some reason I have a feeling’

Thanks for that informative post

As many have said, this is a refinement of the already known £75M contract, the original one was here.
https://bidstats.uk/tenders/2020/W43/737280030

The new details on this, not on the original one, is that delivery is apparently time limited until Feb 21. One could read that as saying that the remaining 9M antibody tests will need to be delivered by then. The contract does allow for an extension for a further 5M, but given thats an extension, its fair to consider that those ones, if ordered, might result in an extended delivery date. Although the contract has the units readacted, we know the 10M/15M figure from the abingdon IPO document.

Not sure how fixed in stone those delivery dates are, as I have no experience in these things.

"antigen lft due aporoval immjnently and already capacity to produce couple million a week, so ahead of us on the latter."

where did you get a "couple of million" ? The article says several million a week, with plans to expand further my the end of the year. Whats the point in minimising their capacity ?

given the "end of the year" is 3 weeks away, I reckon thats 3-4 million a week capacity they'll shortly have.

found it
https://www.ft.com/content/7c0d1d5b-f746-4c50-9513-05d1b6ee27b1

A rapid coronavirus test developed in the UK is close to gaining approval for use by health authorities in England in a boost for the government as it seeks to roll out more mass testing.

The antigen, or lateral flow, test produced by the Derby-based company SureScreen Diagnostics has shown positive results in clinical studies undertaken by researchers at Public Health England and Oxford university, according to two scientists involved in the review.

“We’re delighted about it, it looks like [they] have the real deal,” one of the people said.

Founded in 1991, family-run SureScreen produces technology to screen for drug abuse, infectious disease and other illnesses. The company already sells its Covid-19 rapid antigen test to countries across Europe, including Belgium and Germany.

It has capacity to produce several million tests per week, with plans to expand further by the end of the year.

about got the body of that article, I think its the surescreen test.

that's because unless you having a particular interest, which in our case is as a result in being invested in a test manufacturer, you have zero interest in how a test is administered or what type of test it is. A clinician says you need to take this test, and you take the test.

I don't have shares in a national effort. I have shares in one company.

orders

Thinking a little more regarding the 25th Dec option that DHSC has for cancellation of orders, if you put that date in, then it indicates to me that DHSC had little intention of ordering and using 10-15M antibody tests before then. Little point in including that term in a contract signed 06 oct, if you expected to have acquired and used all the tests in the framework before 25th Dec.

So the consortium have known that it was unlikely to have additional orders out of that framework until the new year.

Is the MHRA by 25th Dec the Xmas present CK referred to?

CK mentioned this once in passing in an oct presentation, and it has been seized on here and reiterated at least 100 times by my reckoning. At that time he was suggesting that it was possible that TT transfer of the mologic antigen test would be completed by christmas or early Jan. The most recent presentation indicated Jan, Christmas was not mentioned. I have no idea why some here are still touting christmas, they are setting themselves up to be disapointed. Not that a couple of weeks is going to be a killer.

it was the 'prospectus' for the proposed abingdon IPO. As lead partner in the RTC, it had to lay out many of the details of the RTC contract. The key info that was in there, that was not previously known is:-
1) A framework contract for 10M units is signed, with 'scope' to extend to 15M. The 1M order came out of this framework.
2) UK gov had provided abingdon with approx £1M for raw materials to make the first orders.
3) UK gov put a clause in the contract that gives them the option to cancel all outstanding orders if MHRA approval for home/sel-test is not granted by 25th December.
4)UK government must give clearance before any sales to anyone other than them. Colin had already indicated this restriction, but it was confirmed in the doc. There was some discussion on here that UK gov may have given clearance, but the way it was stated left me in no doubt that clearance has not been given (as per the date of the doc, which was nov).

"Surely the government has not put an embargo on what the ukrtc can say in terms of overseas sales."
No, they've put an embago on RTC selling to anyone except Uk governement, without prior approval.

"The article states that it is ce marked "
if it wasnt ce marked it couldnt be sold in europe.

trilla, thanks again for the document, it remains by far the most revealing document regarding RTC contract especially given its author is a signee of the contract.